Thursday, October 26, 2017

Details on MDMA's Phase 3 Clinical Trials

MDMA Advances Another Step As Tool to Treat PTSD.

I found it interesting, and compassionate, that those who end up in the placebo control group will have the option to repeat the therapy process with MDMA.

Results from Phase 2:
  • Therapy alone: 23% remission
  • Therapy plus 1 MDMA session: 55% remission
  • Therapy plus 2 MDMA sessions: 61% remission
  • One year out after MDMA sessions: 68% remission
Acceptance is important - some interesting comments:
As a result of both his clinical and imaging work, Nutt has concluded that the common characterization of MDMA as similar to LSD and psilocybin is wrong both in terms of its psychodynamic effects and its effects at the receptor sites. While psilocybin and LSD work through the 5HT2A receptor system, said Nutt, MDMA “dampens down the limbic system—probably through the 5H1A receptor.” MDMA acts so differently that it should not be compared with these other drugs, said Nutt. Rather, it is more accurately characterized as “an empathogenic and anxiolytic.”

 “Unlike the classical psychedelics, which appear to work on depression “by breaking down persistent ruminations, MDMA helps those suffering from PTSD break down their trauma by confronting it,” Nutt commented. “What we think is that under MDMA, the emotions are not so powerful, so people can endure them better.”

No comments:

Post a Comment